Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
      • All Events
      • COVID-19
      • Diabetes
      • Immunology
      • Neuroscience
      • Oncology
      • Cardiovascular
      • COVID-19
      • Diabetes
      • Immunology
      • Men's Health
      • Neuroscience
      • Oncology
  • Medical Education
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the LillyMedical.com website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to LillyMedical.com.

  1. Medical Information Right
  2. Immunology Right
  3. Olumiant (baricitinib) tablets Right
  4. Are there any data about the use of Olumiant® (baricitinib) in pediatric patients with alopecia areata?
Search Olumiant (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Baricitinib

Olumiant® (baricitinib) tablets

1mg, 2mg, 4mg
Full Prescribing Information

baricitinib

1mg, 2mg, 4mg

HCP Fact Sheet | Patient & Caregiver Fact Sheet | FDA Authorization Letter

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

Are there any data about the use of Olumiant® (baricitinib) in pediatric patients with alopecia areata?

The phase 3 BRAVE-AA1 and BRAVE-AA2 clinical trials excluded patients less than 18 years old. There is no ongoing trial evaluating baricitinib in pediatric patients with alopecia areata.

US_cFAQ_BAR064C_PEDIATRIC_USAGE_AA
US_cFAQ_BAR064C_PEDIATRIC_USAGE_AA
en-US

See important safety information, including boxed warning, in the attached prescribing information.

Baricitinib Prescribing Information

Baricitinib is not approved for use in pediatric patients with alopecia areata. Please see prescribing information for approved indication(s).

Ongoing Pediatric Trials

There is currently no ongoing trial evaluating baricitinib in pediatric patients with alopecia areata (AA).

Available Data From the Baricitinib Alopecia Areata Phase 3 Clinical Trials

The efficacy and safety of baricitinib have been evaluated in the following pivotal, phase 3, placebo-controlled trials in adult patients with severe AA

  • BRAVE-AA1 (N=654) compared baricitinib 2-mg or 4-mg monotherapy to placebo in adult patients with ≥50% scalp hair loss, and
  • BRAVE-AA2 (N=546) compared baricitinib 2-mg or 4-mg monotherapy to placebo in adult patients with ≥50% scalp hair loss.1

To be included in BRAVE-AA1 or BRAVE-AA2, patients were required to be at least 18 years old. Pediatric patients were not eligible for enrollment.1

Therefore, no efficacy or safety data are available for pediatric patients in the BRAVE-AA trials.

Enclosed Prescribing Information

OLUMIANT® (baricitinib) tablets, for oral use, Lilly

Reference

The published reference below is available by contacting 1-800-LillyRx (1-800-545-5979).

1King B, Ohyama M, Kwon O, et al; BRAVE-AA investigators. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386(18):1687-1699. https://doi.org/10.1056/nejmoa2110343

Date of Last Review: June 15, 2022

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.4 08/2022 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2022. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    Facebook Twitter
    visit www.phactmi.org
    Lilly